<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025219</url>
  </required_header>
  <id_info>
    <org_study_id>09/B/01</org_study_id>
    <nct_id>NCT01025219</nct_id>
  </id_info>
  <brief_title>A Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction : a Case Control Study</brief_title>
  <acronym>CRACK-ANT</acronym>
  <official_title>A Case Control Study on Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the phenotypic candidates symptoms, in patients with&#xD;
      crack/cocaine addiction, in terms of clinical comorbidities, dimensions of personality, and&#xD;
      neuropsychological evaluations apt to be associated with genetic and genotypic&#xD;
      characterisations, notably on the polymorphisms of the genes coding or regulating&#xD;
      dopaminergic, norepinephrine and serotoninergic systems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genetic studies show an association between drug addiction and the dopaminergic system and&#xD;
      its modulators. Nonetheless, results are contradictory, partially due to the heterogeneity of&#xD;
      the phenotype addiction. Placed on the trafficking route of cocaine, and homogeneously&#xD;
      populated, Martinique is of particular interest for the study of the vulnerability of the&#xD;
      crack/cocaine addiction. In a precedent study, supported by a grant MILDT / INSERM 2000, on&#xD;
      155 men dependent to crack/cocaine and characterised with three clinical dimensions&#xD;
      -sensation seeking, impulsivity and childhood ADHD- we found an association between each&#xD;
      dimension and polymorphisms of DRD2 and DRD4 genes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specific measure that will be related to core objectives of the study is to constitute a sample collection from saliva.</measure>
    <time_frame>The saliva will be collect at the end of the first visit</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Dependence, Cocaine</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Collect 10 ml of Saliva for DNA extraction</intervention_name>
    <description>After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cocaine abuse/dependence according to DSM-IV-TR criteria&#xD;
&#xD;
          -  Come from French West Indies (3 grandparents are African-Caribbean)&#xD;
&#xD;
          -  Sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Men with no cocaine abuse/dependence according to DSM-IV-TR criteria&#xD;
&#xD;
        For the control:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Platelets donor&#xD;
&#xD;
          -  No substance abuse/dependence according to DSM-IV-TR criteria&#xD;
&#xD;
          -  Come from French West Indies (3 grandparents are African-Caribbean)&#xD;
&#xD;
          -  Sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Men refusing a genetic study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme LACOSTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Fort-de-France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme LACOSTE, MD</last_name>
    <phone>596 55 20 44</phone>
    <phone_ext>+596</phone_ext>
    <email>jerome.lacoste@chu-fortdefrance.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jocelyne CRASPAG, Master</last_name>
    <phone>596 59 26 98</phone>
    <phone_ext>+596</phone_ext>
    <email>jocelyne.craspag@chu-fortdefrance.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de psychiatrie et addictologie - CHU de Fort-de-France</name>
      <address>
        <city>Fort-de-France</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyne CRASPAG, Master</last_name>
      <phone>596 59 26 98</phone>
      <phone_ext>+596</phone_ext>
      <email>jocelyne.craspag@chu-fortdefrance.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mickaëlle ROSE, Master</last_name>
      <phone>596 59 26 98</phone>
      <phone_ext>+596</phone_ext>
      <email>mickaelle.rose@chu-fortdefrance.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jérôme LACOSTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>March 21, 2011</last_update_submitted>
  <last_update_submitted_qc>March 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>RIAM Daniel</name_title>
    <organization>CHU de Fort-de-France</organization>
  </responsible_party>
  <keyword>Diagnosis of dependence on cocaine according to DSM-IV-TR criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

